hrp0084fc7.6 | Growth-promoting therapies | ESPE2015
, Jaron-Mendelson Michal
, Amitzi Leanne
, Koren Ronit
, Hart Gili
Background, objective, and hypotheses: OPKO Biologics has produced a long-acting human GH (hGH), MOD-4023, containing copies of a naturally-occurring C-terminal peptide (CTP) to markedly increase GHs in vivo residence. We describe the construction and validation of a pharmacokinetic (PK)/pharmacodynamics (PD) model to characterise the relationship between MOD-4023 dose, MOD-4023 serum concentrations (Cserum), and IGF1 responses in healthy adults, GH-deficient (G...